AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

AbbVie (ABBV) is set to report Q2 2025 earnings on July 31, with consensus forecasting EPS of $2.95 (+11.3% YoY) and revenues of $15.04 billion (+4% YoY). Despite a history of beating EPS estimates over the past four quarters, the company's current Zacks Earnings ESP of -1.82% combined with a Zacks Rank #3 suggests it is not a strong candidate for an earnings beat this quarter, potentially exposing the stock to downside if actual results miss expectations.

Analysis

AbbVie is approaching its Q2 2025 earnings release with consensus expectations pointing to robust year-over-year growth, including an 11.3% increase in EPS to $2.95 and a 4% rise in revenue to $15.04 billion. While the consensus EPS estimate has seen a minor upward revision of 0.12% in the last 30 days, more recent proprietary signals present a cautious outlook. The company's Zacks Earnings ESP (Expected Surprise Prediction) is a negative 1.82%, indicating that the most recent analyst estimates are trending below the broader consensus. This suggests a potential for downward earnings pressure. Despite a strong history of beating EPS estimates for the last four consecutive quarters, the combination of a negative ESP and a Zacks Rank #3 (Hold) makes it statistically difficult to predict another earnings beat. This contrasts with the broader growth narrative and introduces a significant element of uncertainty ahead of the report. The situation for peer Merck, which faces expected YoY declines and its own conflicting signals, underscores a mixed environment for the large-cap pharmaceutical sector.

Key Decisions for Investors

• Given the negative Earnings ESP of -1.82%, investors should exercise caution, as the probability of a positive earnings surprise is considered low according to the provided model, increasing downside risk if results miss expectations.
• Focus should be placed on management's forward-looking guidance during the earnings call, as this will be more critical than the headline beat or miss for determining the stock's sustainable direction.
• While AbbVie has a four-quarter streak of beating EPS estimates, the current bearish signal from the ESP suggests this historical performance may not be a reliable indicator for the upcoming report, warranting a potential reassessment of short-term expectations.